These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 33146206)

  • 1. Targeted ferritin nanoparticle encapsulating CpG oligodeoxynucleotides induces tumor-associated macrophage M2 phenotype polarization into M1 phenotype and inhibits tumor growth.
    Shan H; Dou W; Zhang Y; Qi M
    Nanoscale; 2020 Nov; 12(43):22268-22280. PubMed ID: 33146206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
    Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
    Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
    [No Abstract]   [Full Text] [Related]  

  • 3. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages.
    Ngambenjawong C; Cieslewicz M; Schellinger JG; Pun SH
    J Control Release; 2016 Feb; 224():103-111. PubMed ID: 26772876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles.
    Chong L; Jiang YW; Wang D; Chang P; Xu K; Li J
    J Nanobiotechnology; 2023 Oct; 21(1):401. PubMed ID: 37907987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surface Modification of Polymeric Nanoparticles with M2pep Peptide for Drug Delivery to Tumor-Associated Macrophages.
    Pang L; Pei Y; Uzunalli G; Hyun H; Lyle LT; Yeo Y
    Pharm Res; 2019 Mar; 36(4):65. PubMed ID: 30859335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Stability and Affinity Optimization of an M2 Macrophage-Targeting Peptide (M2pep).
    Ngambenjawong C; Gustafson HH; Pineda JM; Kacherovsky NA; Cieslewicz M; Pun SH
    Theranostics; 2016; 6(9):1403-14. PubMed ID: 27375788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective targeting of tumor associated macrophages in different tumor models.
    Kakoschky B; Pleli T; Schmithals C; Zeuzem S; Brüne B; Vogl TJ; Korf HW; Weigert A; Piiper A
    PLoS One; 2018; 13(2):e0193015. PubMed ID: 29447241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
    Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
    ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival.
    Cieslewicz M; Tang J; Yu JL; Cao H; Zavaljevski M; Motoyama K; Lieber A; Raines EW; Pun SH
    Proc Natl Acad Sci U S A; 2013 Oct; 110(40):15919-24. PubMed ID: 24046373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for Prostate Cancer Therapy.
    Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
    Mol Pharm; 2023 Nov; 20(11):5921-5936. PubMed ID: 37874541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer.
    Chen Y; Gong L; Cao Y; Liu Z; Wang Y; Cheng H; Feng Y; Yao S; Yin Y; Wu Z; Huang Z
    J Control Release; 2024 Feb; 366():395-409. PubMed ID: 38184235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bio-Responsive nanoparticle for tumor targeting and enhanced photo-immunotherapy.
    Tian D; Qin F; Zhao H; Zhang C; Wang H; Liu N; Ai Y
    Colloids Surf B Biointerfaces; 2021 Jun; 202():111681. PubMed ID: 33714187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
    Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
    J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-assembled tetrahedral framework nucleic acid mediates tumor-associated macrophage reprogramming and restores antitumor immunity.
    Qian H; Zhou T; Fu Y; Guo M; Yang W; Zhang D; Fang W; Yao M; Shi H; Chai C; Cheng W; Ding S; Chen T
    Mol Ther Nucleic Acids; 2022 Mar; 27():763-773. PubMed ID: 35116188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
    Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
    Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma.
    Han S; Bao X; Zou Y; Wang L; Li Y; Yang L; Liao A; Zhang X; Jiang X; Liang D; Dai Y; Zheng QC; Yu Z; Guo J
    Sci Adv; 2023 Jul; 9(29):eadg2697. PubMed ID: 37467325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy.
    Figueiredo P; Lepland A; Scodeller P; Fontana F; Torrieri G; Tiboni M; Shahbazi MA; Casettari L; Kostiainen MA; Hirvonen J; Teesalu T; Santos HA
    Acta Biomater; 2021 Oct; 133():231-243. PubMed ID: 33011297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer.
    Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
    Eur J Pharm Sci; 2023 Jun; 185():106427. PubMed ID: 36948408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer.
    Esser AK; Ross MH; Fontana F; Su X; Gabay A; Fox GC; Xu Y; Xiang J; Schmieder AH; Yang X; Cui G; Scott M; Achilefu S; Chauhan J; Fletcher S; Lanza GM; Weilbaecher KN
    Theranostics; 2020; 10(17):7510-7526. PubMed ID: 32685002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
    Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
    Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.